Hidradenitis Suppurativa Pipeline Review, H2 2016: Therapeutics Report Detailing 6 Companies & 10 Molecules - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Hidradenitis Suppurativa - Pipeline Review, H2 2016" report to their offering.

Hidradenitis Suppurativa pipeline therapeutics constitutes close to 10 molecules. which approximately 10 molecules are developed by Companies. Our latest report Hidradenitis Suppurativa - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hidradenitis Suppurativa Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 5 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Hidradenitis Suppurativa Overview
  3. Therapeutics Development
  4. Pipeline Products for Hidradenitis Suppurativa - Overview
  5. Pipeline Products for Hidradenitis Suppurativa - Comparative Analysis
  6. Hidradenitis Suppurativa - Therapeutics under Development by Companies
  7. Hidradenitis Suppurativa - Therapeutics under Investigation by Universities/Institutes
  8. Hidradenitis Suppurativa Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Hidradenitis Suppurativa - Products under Development by Companies
  13. Hidradenitis Suppurativa - Products under Investigation by Universities/Institutes
  14. Hidradenitis Suppurativa - Companies Involved in Therapeutics Development
  • Cellceutix Corporation
  • Celtaxsys, Inc.
  • Delenex Therapeutics AG
  • Johnson & Johnson
  • Novartis AG
  • Sandoz International GmbH

For more information about this report visit http://www.researchandmarkets.com/research/drs2xn/hidradenitis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs